ReviewInfectious diseases and therapy2021
Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations.
Review in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 82 citations in OpenAlex.
- The CCR2 inflammatory pathway is a target for improving severe disease and pulmonary inflammation in experimental COVID-19.Virulence · 2026Article
- Chitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary-Thyroid Axis Dysfunction via Redox-Inflammatory Signaling Modulation in Rats.International journal of molecular sciences · 2026Article
- Hot melt extruded Kyungohkgo attenuates skeletal muscle atrophy by downregulating the FOXO3a/MuRF-1/atrogin-1 axis.Scientific reports · 2026Article
- Anti-Inflammatory Effect of Resiniferatoxin During Gingival Tissue Inflammation After Mechanical Pulp Damage in a Murine Experimental Model.International journal of molecular sciences · 2026Article
- Integrating UPLC-HR-MS, network pharmacology and experimental validation to reveal the potential mechanism of Fuzheng Bixie granules in treating acute lung injury.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats.Scientific reports · 2026Article
- Influence of short-term dexamethasone-induced stress on behavioral, physiological and reproductive performance of growing rabbit bucks.BMC veterinary research · 2026Article
- Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2.Multidisciplinary respiratory medicine · 2025Article
- COVID-19 management in patients with comorbid conditions.World journal of virology · 2025Review
- Inflammatory microenvironment-responsive nanomicelles for acute lung injury therapy: ROS-scavenging and macrophage repolarization.Materials today. Bio · 2025Article
- Dexamethasone in coronavirus disease 2019 care: Dosage and utilization insights.World journal of virology · 2025Article
- Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.Military Medical Research · 2024Review
- The IRE1α-XBP1 arm of the unfolded protein response is a host factor activated in SARS-CoV-2 infection.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- The Effects of Remdesivir and Dexamethasone on Renal Sirtuin-1 Expression and Renal Function in Male Rats.Applied biochemistry and biotechnology · 2024Article
- Pulmonary Delivery of Anti-microRNA Oligonucleotide and Glycyrrhizic Acid Using Ternary Peptide Micelles for the Treatment of Acute Lung Injury.Biomaterials research · 2024Article
- The glycosaminoglycan-binding chemokine fragment CXCL9(74-103) reduces inflammation and tissue damage in mouse models of coronavirus infection.Frontiers in immunology · 2024Article
- Quantum DFT studies on the drug delivery of favipiravir using pristine and functionalized chitosan nanoparticles.Scientific reports · 2023Article
- The Effects of ProbioticInternational journal of molecular sciences · 2023Article
- Article
- Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare community has raced to find effective therapeutic agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, dexamethasone is the first and an important therapeutic to significantly reduce the risk of death in COVID-19 patients with severe disease. Due to powerful anti-inflammatory and immunosuppressive effects, dexamethasone could attenuate SARS-CoV-2-induced uncontrolled cytokine storm, severe acute respiratory distress syndrome and lung injury. Nevertheless, dexamethasone treatment is a double-edged sword, as numerous studies have revealed that it has significant adverse impacts later in life. In this article, we reviewed the literature regarding the adverse effects of dexamethasone administration on different organ systems as well as related disease pathogenesis in an attempt to clarify the potential harms that may arise in COVID-19 patients receiving dexamethasone treatment. Overall, taking the threat of COVID-19 pandemic into account, we think it is necessary to apply dexamethasone as a pharmaceutical therapy in critical patients. However, its adverse side effects cannot be ignored. Our review will help medical professionals in the prognosis and follow-up of patients treated with dexamethasone. In addition, given that a considerable amount of uncertainty, confusion and even controversy still exist, further studies and more clinical trials are urgently needed to improve our understanding of the parameters and the effects of dexamethasone on patients with SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.